P W Collins

List of Publications by Year
in descending order

159 papers	9,500 citations	34105 52 h-index	42399 92 g-index
163 all docs	163 docs citations	163 times ranked	4999 citing authors

#	Article	IF	Citations
1	Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood, 2007, 109, 1870-1877.	1.4	646
2	Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Journal of Thrombosis and Haemostasis, 2012, 10, 622-631.	3.8	395
3	The use of fibrinogen concentrate to correct hypofibrinogenaemia rapidly during obstetric haemorrhage. International Journal of Obstetric Anesthesia, 2010, 19, 218-223.	0.4	301
4	Breakâ€through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. Journal of Thrombosis and Haemostasis, 2009, 7, 413-420.	3.8	295
5	Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood, 2012, 120, 47-55.	1.4	284
6	Acquired hemophilia <scp>A</scp>: Updated review of evidence and treatment guidance. American Journal of Hematology, 2017, 92, 695-705.	4.1	267
7	Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study. Blood, 2014, 124, 1727-1736.	1.4	196
8	Blood transfusion and the anaesthetist: management of massive haemorrhage. Anaesthesia, 2010, 65, 1153-1161.	3.8	193
9	Diagnosis and treatment of factor <scp>VIII</scp> and <scp>IX</scp> inhibitors in congenital haemophilia: (4th edition). British Journal of Haematology, 2013, 160, 153-170.	2.5	192
10	International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica, 2020, 105, 1791-1801.	3.5	182
11	Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood, 2012, 119, 612-618.	1.4	181
12	Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. Journal of Thrombosis and Haemostasis, 2010, 8, 269-275.	3.8	176
13	Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood, 2011, 117, 6367-6370.	1.4	173
14	Haemostatic monitoring during postpartum haemorrhage and implications for management. British Journal of Anaesthesia, 2012, 109, 851-863.	3.4	171
15	Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia, 2011, 17, 2-10.	2.1	170
16	Standard haemostatic tests following major obstetric haemorrhage. International Journal of Obstetric Anesthesia, 2011, 20, 135-141.	0.4	168
17	Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood, 2014, 124, 3880-3886.	1.4	163
18	The use of viscoelastic haemostatic assays in the management of major bleeding. British Journal of Haematology, 2018, 182, 789-806.	2.5	160

#	Article	IF	Citations
19	Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Research Notes, 2010, 3, 161.	1.4	149
20	Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. British Journal of Haematology, 2006, 135, 220-227.	2.5	144
21	Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albuminâ€free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A¹. Haemophilia, 2004, 10, 428-437.	2.1	143
22	Viscoelastometric-guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2, a double-blind randomized controlled trial. British Journal of Anaesthesia, 2017, 119, 411-421.	3.4	143
23	Coordinated Membrane Ballooning and Procoagulant Spreading in Human Platelets. Circulation, 2015, 132, 1414-1424.	1.6	139
24	A population based, unselected, consecutive cohort of patients with acquired haemophiliaÂA. British Journal of Haematology, 2004, 124, 86-90.	2.5	134
25	Efficacy and safety of secondary prophylactic vs. onâ€demand sucroseâ€formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13â€month crossover study. Journal of Thrombosis and Haemostasis, 2010, 8, 83-89.	3.8	129
26	Haemostatic management of obstetric haemorrhage. Anaesthesia, 2015, 70, 78.	3.8	129
27	A United Kingdom Haemophilia Centre Doctorsâ€™ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. British Journal of Haematology, 2010, 149, 498-507.	2.5	123
28	Diagnosis and management of acquired coagulation inhibitors: a guideline from <scp>UKHCDO</scp>. British Journal of Haematology, 2013, 162, 758-773.	2.5	118
29	Comparative pharmacokinetics of plasmaâ€and albuminâ€free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed ageâ€related differences and implications for dose tailoring. Journal of Thrombosis and Haemostasis, 2010, 8, 730-736.	3.8	115
30	Phospholipid-esterified Eicosanoids Are Generated in Agonist-activated Human Platelets and Enhance Tissue Factor-dependent Thrombin Generation. Journal of Biological Chemistry, 2010, 285, 6891-6903.	3.4	115
31	Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. Blood, 2014, 124, 3389-3397.	1.4	110
32	Changing patterns of bleeding in patients with severe haemophilia A. Haemophilia, 2009, 15, 1210-1214.	2.1	109
33	Treatment of acquired hemophilia A. Journal of Thrombosis and Haemostasis, 2007, 5, 893-900.	3.8	107
34	Theoretical modelling of fibrinogen supplementation with therapeutic plasma, cryoprecipitate, or fibrinogen concentrate. British Journal of Anaesthesia, 2014, 113, 585-595.	3.4	106
35	Management of acquired haemophilia A. Journal of Thrombosis and Haemostasis, 2011, 9, 226-235.	3.8	105
36	Management of coagulopathy associated with postpartum hemorrhage: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2016, 14, 205-210.	3.8	103

#	Article	IF	Citations
37	The use of enhanced halfâ€life coagulation factor concentrates in routine clinical practice: guidance from <scp>UKHCDO</scp>. Haemophilia, 2016, 22, 487-498.	2.1	97
38	Advances in the understanding of acquired haemophilia A: implications for clinical practice. British Journal of Haematology, 2010, 148, 183-194.	2.5	94
39	Personalized prophylaxis. Haemophilia, 2012, 18, 131-135.	2.1	80
40	Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease. Journal of Experimental Medicine, 2017, 214, 2121-2138.	8.5	78
41	Measurement of blood loss during postpartum haemorrhage. International Journal of Obstetric Anesthesia, 2015, 24, 8-14.	0.4	77
42	Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia, 2018, 24, 344-347.	2.1	73
43	Core outcome sets for prevention and treatment of postpartum haemorrhage: an international Delphi consensus study. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 83-93.	2.3	70
44	Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. Journal of Thrombosis and Haemostasis, 2009, 7, 787-794.	3.8	66
45	Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophiliaÂA or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2017, 15, 2461-2465.	3.8	65
46	Characterization of platelet aminophospholipid externalization reveals fatty acids as molecular determinants that regulate coagulation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5875-5880.	7.1	62
47	Management of postpartum haemorrhage: from research into practice, a narrative review of the literature and the Cardiff experience. International Journal of Obstetric Anesthesia, 2019, 37, 106-117.	0.4	62
48	The haematological features and transfusion management of women who required massive transfusion for major obstetric haemorrhage in the <scp>UK</scp>: a population based study. British Journal of Haematology, 2016, 172, 616-624.	2.5	61
49	Viscoelastometry guided fresh frozen plasma infusion for postpartum haemorrhage: OBS2, an observational study. British Journal of Anaesthesia, 2017, 119, 422-434.	3.4	60
50	Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9â€GP), a glycoPEGylated recombinant factor IX. Journal of Thrombosis and Haemostasis, 2012, 10, 2305-2312.	3.8	58
51	Association of peak factor <scp>VIII</scp> levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokineticâ€guided prophylaxis. Haemophilia, 2016, 22, 514-520.	2.1	58
52	When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2016, 14, 1105-1109.	3.8	54
53	Platelet Control of Fibrin Distribution and Microelasticity in Thrombus Formation Under Flow. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 692-699.	2.4	53
54	Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigmâ„¢4). Thrombosis Research, 2016, 141, 69-76.	1.7	52

#	Article	IF	Citations
55	Combined Quantification of the Global Proteome, Phosphoproteome, and Proteolytic Cleavage to Characterize Altered Platelet Functions in the Human Scott Syndrome. Molecular and Cellular Proteomics, 2016, 15, 3154-3169.	3.8	52
56	Role of enhanced halfâ€life factor <scp>VIII</scp> and <scp>IX</scp> in the treatment of haemophilia. British Journal of Haematology, 2015, 169, 768-776.	2.5	51
57	Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study. Haemophilia, 2019, 25, 205-212.	2.1	51
58	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 535-548.	2.3	50
59	Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemophilia, 2008, 14, 49-55.	2.1	49
60	Measurement of factorÂVIII pharmacokinetics in routine clinical practice. Journal of Thrombosis and Haemostasis, 2013, 11, 180-182.	3.8	49
61	Platelet heterogeneity in activation-induced glycoprotein shedding: functional effects. Blood Advances, 2018, 2, 2320-2331.	5.2	45
62	Human platelets generate phospholipid-esterified prostaglandins via cyclooxygenase-1 that are inhibited by low dose aspirin supplementation. Journal of Lipid Research, 2013, 54, 3085-3097.	4.2	44
63	Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood, 2021, 137, 1818-1827.	1.4	43
64	The incidence of factor <scp>VIII</scp> inhibitors in severe haemophilia A following a major switch from fullâ€length to Bâ€domainâ€deleted factor <scp>VIII</scp>: a prospective cohort comparison. Haemophilia, 2015, 21, 219-226.	2.1	41
65	Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?. Blood Reviews, 2018, 32, 265-271.	5.7	41
66	Networks of enzymatically oxidized membrane lipids support calcium-dependent coagulation factor binding to maintain hemostasis. Science Signaling, 2017, 10, .	3.6	40
67	Intracranial haemorrhage in children with inherited bleeding disorders in the <scp>UK</scp> 2003â€2015: A national cohort study. Haemophilia, 2018, 24, 641-647.	2.1	40
68	Increased bleeding associated with protease inhibitor therapy in HIV-positive patients with bleeding disorders. British Journal of Haematology, 1999, 107, 556-559.	2.5	38
69	Enzymatically oxidized phospholipids restore thrombin generation in coagulation factor deficiencies. JCI Insight, 2018, 3, .	5.0	36
70	Incidence of postpartum haemorrhage defined by quantitative blood loss measurement: a national cohort. BMC Pregnancy and Childbirth, 2020, 20, 271.	2.4	34
71	Endotheliumâ€derived relaxing factor and nitroprusside compared in noradrenalineâ€and K+â€contracted rabbit and rat aortae.. Journal of Physiology, 1988, 400, 395-404.	2.9	32
72	Pilot study of an Internet-based electronic patient treatment record and communication system for haemophilia, Advoy.com. Haemophilia, 2003, 9, 285-291.	2.1	31

#	Article	IF	Citations
73	Therapeutic challenges in acquired factor VIII deficiency. Hematology American Society of Hematology Education Program, 2012, 2012, 369-374.	2.5	31
74	Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: study protocol for a randomised controlled trial. Trials, 2015, 16, 169.	1.6	31
75	Unclassified bleeding disorders: outcome of haemostatic challenges following tranexamic acid and/or desmopressin. Haemophilia, 2016, 22, 285-291.	2.1	30
76	Reduction in massive postpartum haemorrhage and red blood cell transfusion during a national quality improvement project, Obstetric Bleeding Strategy for Wales, OBS Cymru: an observational study. BMC Pregnancy and Childbirth, 2021, 21, 377.	2.4	29
77	Platelet count and transfusion requirements during moderate or severe postpartum haemorrhage. Anaesthesia, 2016, 71, 648-656.	3.8	28
78	National audit of the use of fibrinogen concentrate to correct hypofibrinogenaemia. Transfusion Medicine, 2012, 22, 350-355.	1.1	27
79	Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies. Haemophilia, 2019, 25, 398-407.	2.1	27
80	Type 1 von Willebrand disease: application of emerging data to clinical practice. Haemophilia, 2008, 14, 685-696.	2.1	26
81	Facilitating the implementation of pharmacokineticâ€guided dosing of prophylaxis in haemophilia care by discrete choice experiment. Haemophilia, 2016, 22, e1-e10.	2.1	26
82	Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex. Thrombosis Research, 2016, 145, 84-92.	1.7	25
83	Firstâ€line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties. Haemophilia, 2017, 23, 654-659.	2.1	25
84	Recombinant longâ€acting glyco<scp>PEG</scp>ylated factor <scp>IX</scp> (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials. Haemophilia, 2016, 22, 507-513.	2.1	24
85	Management of acquired haemophilia A - more questions than answers. Blood Coagulation and Fibrinolysis, 2003, 14, S23-S27.	1.0	23
86	Pharmacokinetic properties of <scp>IB</scp>1001, an investigational recombinant factor <scp>IX</scp>, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. Haemophilia, 2012, 18, 881-887.	2.1	23
87	Phospholipid membranes drive abdominal aortic aneurysm development through stimulating coagulation factor activity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8038-8047.	7.1	22
88	The haemtrack home therapy reporting system: Design, implementation, strengths and weaknesses: A report from UK Haemophilia Centre Doctors Organisation. Haemophilia, 2017, 23, 728-735.	2.1	20
89	Utility of viscoelastography with TEG 6s to direct management of haemostasis during obstetric haemorrhage: a prospective observational study. International Journal of Obstetric Anesthesia, 2021, 47, 103192.	0.4	20
90	The sensitivity and specificity of rotational thromboelastometry (ROTEM) to detect coagulopathy during moderate and severe postpartum haemorrhage: a prospective observational study. International Journal of Obstetric Anesthesia, 2022, 49, 103238.	0.4	20

#	Article	IF	Citations
91	Therapeutic challenges in acquired factor VIII deficiency. Hematology American Society of Hematology Education Program, 2012, 2012, 369-74.	2.5	20
92	Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis. Thrombosis and Haemostasis, 2020, 120, 728-736.	3.4	19
93	Clinical phenotype of severe and moderate haemophilia: Who should receive prophylaxis and what is the target trough level?. Haemophilia, 2021, 27, 192-198.	2.1	19
94	The incidence, aetiology, and coagulation management of massive postpartum haemorrhage: a two-year national prospective cohort study. International Journal of Obstetric Anesthesia, 2021, 47, 102983.	0.4	19
95	Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 528-541.	2.3	18
96	Repair of the ependyma in hydrocephalic brains. Neuropathology and Applied Neurobiology, 1990, 16, 45-56.	3.2	17
97	Novel therapies for immune tolerance in haemophilia A. Haemophilia, 2006, 12, 94-101.	2.1	16
98	Joint health scores in a haemophilia A cohort from Pakistan with minimal or no access to factor <scp>VIII</scp> concentrate: correlation with thrombin generation and underlying mutation. Haemophilia, 2014, 20, 426-434.	2.1	16
99	Identification and quantification of aminophospholipid molecular species on the surface of apoptotic and activated cells. Nature Protocols, 2014, 9, 51-63.	12.0	16
100	DioxolaneA3-phosphatidylethanolamines are generated by human platelets and stimulate neutrophil integrin expression. Redox Biology, 2017, 11, 663-672.	9.0	16
101	Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update. Haemophilia, 2021, 27, 932-937.	2.1	16
102	Human Platelets Utilize Cycloxygenase-1 to Generate Dioxolane A3, a Neutrophil-activating Eicosanoid. Journal of Biological Chemistry, 2016, 291, 13448-13464.	3.4	15
103	Retrospective Review of a Prothrombin Complex Concentrate (Beriplex P/N) for the Management of Perioperative Bleeding Unrelated to Oral Anticoagulation. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 1159-1169.	1.7	15
104	Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study. Blood Advances, 2022, 6, 902-908.	5.2	15
105	Pharmacokinetics, safety and efficacy of a recombinant factor <scp>IX</scp> product, trenonacog alfa in previously treated haemophilia B patients. Haemophilia, 2018, 24, 104-112.	2.1	14
106	Designing and implementing an all Wales postpartum haemorrhage quality improvement project: OBS Cymru (the Obstetric Bleeding Strategy for Wales). BMJ Open Quality, 2020, 9, e000854.	1.1	14
107	Calcium retention and increased vascular reactivity caused by a hypothalamic sodium transport inhibitor. Clinical Science, 1988, 75, 197-202.	4.3	13
108	High concentrations of coagulation factor VIII and thrombosis: is the factor VIII-binding domain of von Willebrand factor implicated?. British Journal of Haematology, 2001, 113, 655-657.	2.5	13

#	Article	IF	Citations
109	Factor V Leiden and the common haemochromatosis mutation HFE C282Y: is there an association in familial venous thromboembolic disease?. British Journal of Haematology, 1999, 107, 210-212.	2.5	12
110	Risk factors for cardiovascular disease and hormone therapy in women. Heart, 2006, 92, iii24-iii28.	2.9	12
111	Theoretical Modeling of Coagulation Management With Therapeutic Plasma or Prothrombin Complex Concentrate. Anesthesia and Analgesia, 2017, 125, 1471-1474.	2.2	12
112	The role of procoagulant phospholipids on the surface of circulating blood cells in thrombosis and haemostasis. Open Biology, 2022, 12, 210318.	3.6	12
113	Minimal dataset for postâ€registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2017, 15, 1878-1881.	3.8	11
114	The immunogenicity of ReFacto <scp>AF</scp> (moroctocog alfa <scp>AF</scp>â€<scp>CC</scp>) in previously untreated patients with haemophilia A in the United Kingdom. Haemophilia, 2018, 24, 896-901.	2.1	11
115	Specific analysis of the intron 22 Xba I polymorphism of the human factor VIII gene using long-distance PCR. British Journal of Haematology, 1999, 107, 566-568.	2.5	10
116	Commentary on Reconstituting Fibrinogen Concentrate to Maintain Blinding in a Double-blind, Randomized Trial in an Emergency Setting. Journal of Emergency Medicine, 2016, 50, 104-107.e1.	0.7	10
117	The bleeding phenotype in people with nonsevere hemophilia. Blood Advances, 2022, 6, 4256-4265.	5.2	10
118	Subependymal cells provide a faster response to ependymal injury than astrocytes in the hydrocephalic brain. Neuropathology and Applied Neurobiology, 1992, 18, 387-394.	3.2	9
119	Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. Journal of Thrombosis and Haemostasis, 2018, 16, 2196-2207.	3.8	9
120	Selective angiographic embolization for recurrent elbow and knee haemarthroses in haemophilia: a retrospective case series. Haemophilia, 2015, 21, e226-8.	2.1	8
121	Mycophenolate mofetil as adjunctive therapy in acquired haemophilia A. Haemophilia, 2019, 25, e59-e65.	2.1	8
122	A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients. Thrombosis and Haemostasis, 2020, 120, 747-757.	3.4	8
123	Acquired Haemophilia: Clinical and Demographic Data.Results of European Acquired Haemophilia Registry (EACH2).. Blood, 2010, 116, 1398-1398.	1.4	8
124	Perioperative replacement therapy in haemophilia B: An appeal to â€œBâ€•more precise. Haemophilia, 2018, 24, 611-618.	2.1	7
125	Inhibitor Eradication In Acquired Haemophilia A: Final Results of European Acquired Haemophilia Registry (EACH2). Blood, 2010, 116, 715-715.	1.4	7
126	Venous Thromboembolic Prophylaxis for Transurethral Prostatectomy: Practice among British Urologists. Journal of the Royal Society of Medicine, 2002, 95, 130-131.	2.0	6

#	Article	IF	Citations
127	Introduction of standardized, cumulative quantitative measurement of blood loss into routine maternity care. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 1491-1497.	1.5	6
128	Comparison of haematological indices and transfusion management in severe and massive postpartum haemorrhage: analysis of a two-year national prospective observational study. International Journal of Obstetric Anesthesia, 2022, 50, 103547.	0.4	6
129	A new polymorphism in the human factor VIII gene: implications for linkage analysis in haemophilia A and for the evolution of int22h sequences. British Journal of Haematology, 2000, 111, 544-548.	2.5	5
130	Experience of immune tolerance in a carrier of severe haemophilia A with inhibitor development postâ€surgery. Haemophilia, 2017, 23, e234-e235.	2.1	5
131	The procoagulant activity of tissue factor expressed on fibroblasts is increased by tissue factor-negative extracellular vesicles. PLoS ONE, 2020, 15, e0240189.	2.5	5
132	Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B. The Cochrane Library, 2021, 2021, CD014201.	2.8	5
133	Management of Bleeding In Acquired Hemophilia: Results of the European Acquired Hemophilia Registry (EACH2). Blood, 2010, 116, 716-716.	1.4	5
134	Acquired Haemophilia A and Pregnancy/Postpartum â€“ a Report From a European Registry. Blood, 2010, 116, 717-717.	1.4	5
135	Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis. Blood, 2016, 128, 2576-2576.	1.4	3
136	Real life experiences of a <scp>PK</scp> dosing studyâ€”Challenges and lessons learned.. Haemophilia, 2018, 24, e145-e148.	2.1	2
137	Global Haemostasis in Critically Ill Patients with Sepsis: Evidence for a Prothrombotic State.. Blood, 2005, 106, 2140-2140.	1.4	2
138	Clinical Implications of Pharmacokinetic Variables in the Management of Patients with Severe Hemophilia A.. Blood, 2006, 108, 1041-1041.	1.4	2
139	Effect of Normal Variation in Factor VIII Pharmacokinetics on Prophylactic Dosing Requirements in Severe Classical Hemophilia.. Blood, 2008, 112, 1222-1222.	1.4	2
140	Use of a Population Pharmacokinetic Model of ADVATE In Pediatric and Adult Patients with Hemophilia A Permits Limited Blood Sampling for Individual Dose Tailoring.. Blood, 2010, 116, 1416-1416.	1.4	2
141	Inhibitors, what is the risk of treatment intensity?. Journal of Thrombosis and Haemostasis, 2007, 5, 1380-1382.	3.8	1
142	Predicting blood loss using novel thromboelastometry assays in cardiac surgery. Anaesthesia, 2010, 65, 99-100.	3.8	1
143	UKHCDO Acquired Haemophilia Study: A Complete National Cohort.. Blood, 2005, 106, 322-322.	1.4	1
144	Population Pharmacokinetic Model of ADVATE in Pediatric and Adult Patients with Hemophilia A.. Blood, 2009, 114, 3492-3492.	1.4	1

#	Article	IF	Citations
145	Failure of Thromboxane Synthetase Inhibition to Improve Exercise Capacity in Angina. Clinical Science, 1983, 65, 36P-36P.	4.3	0
146	Alpha Adrenoceptor Blockade Improves Exercise Tolerance in Angina Pectoris. Clinical Science, 1984, 66, 40P-40P.	4.3	0
147	Endothelium-Dep Endent Calcium Fluxes in Rabbit Aorta. Clinical Science, 1984, 67, 28P-28P.	0.0	0
148	Thrombin generation during cardiac bypass surgery. Anaesthesia, 2008, 63, 1272-1272.	3.8	0
149	Rate of change of clot flexibility during cardiac bypass surgery. Anaesthesia, 2008, 63, 1273-1273.	3.8	0
150	Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. Journal of Thrombosis and Haemostasis, 2010, , no.	3.8	0
151	Plasma Microparticles Have Different Effects on Thrombin Generation in Platelet-Rich and Platelet-Poor Plasma.. Blood, 2006, 108, 1760-1760.	1.4	0
152	Prospective Analysis of Bruising in Children with and without an Inherited Bleeding Disorder.. Blood, 2006, 108, 1024-1024.	1.4	0
153	Rituximab for Treatment of Resistant Inhibitors in Severe Haemophilia a: A Consecutive National Cohort.. Blood, 2008, 112, 2275-2275.	1.4	0
154	Pharmacokinetic Behavior of IB1001, An Investigational Recombinant Factor IX, in Patients with Hemophilia B: Repeat Pharmacokinetic Study and Subgroup Analysis. Blood, 2011, 118, 2267-2267.	1.4	0
155	Human-Cl Rhfviii Effectively and Safely Prevents Bleeding Episodes in Previously Treated Adult Patients with Severe Haemophilia A. Blood, 2012, 120, 1132-1132.	1.4	0
156	Title is missing!. , 2020, 15, e0240189.		0
157	Title is missing!. , 2020, 15, e0240189.		0
158	Title is missing!. , 2020, 15, e0240189.		0
159	Title is missing!. , 2020, 15, e0240189.		0